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Aims FK506-binding protein (FKBP) 12 is an inhibitor of transforming growth factor (TGF)-b type I recep-
tors. Several lines of evidence support the view that TGF-b stimulates vascular smooth muscle cell
(VSMC) proliferation and matrix accumulation. We investigated the effect of FK506, also known as
tacrolimus, on cellular proliferation and on matrix protein production in human VSMCs.
Methods and results We measured cell proliferation with ﬂow cytometry using BrdU incorporation and
ﬂuorimetrically by measuring DNA concentration with Hoechst 33258. Western blot assay of whole-cell
lysates was used to measure the levels of signalling proteins involved in proliferative pathways, in par-
ticular b-catenin, pErk, pAkt, pmTOR, and cyclin D1. Collagen synthesis was also investigated by
Western blotting. The TGF-b signal was studied by both Western blotting and confocal microscopy.
We used the SiRNA technique for FKBP12 gene silencing. Our results show that FK506 stimulates
VSMC proliferation and collagen type I production. FK506 enhanced b-catenin levels and activated
the extracellular signal-regulated kinase, Akt, and mammalian target of rapamycin kinase, which are
important effectors of proliferation. Accordingly, cyclin D1 expression was increased. We also demon-
strate that FK506 activates the TGF-b signal in VSMCs and that, through this mechanism, it stimulates
cell proliferation.
Conclusion FK506 can act as a growth factor for VSMCs.
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1. Introduction
A large body of evidence suggests that transforming growth
factor (TGF)-b simulates intimal growth in vascular smooth
muscle cells (VSMCs) by inducing cellular proliferation and
matrix accumulation.
1–6 Direct transfer of the TGF-b gene
into arteries stimulates ﬁbrocellular hyperplasia.
3 Systemic
infusion of TGF-b protein in animal models of arterial injury
1–
4 promotes intimal growth. Moreover, TGF-b antagonists
decrease intimal growth in animal models of arterial injury.
5,6
TGF-b is a pleiotropic cytokine important in the control of
cell proliferation and differentiation, embryonic develop-
ment, angiogenesis, and wound healing.
4,7,8 It can trigger
a variety of biological responses by activating Smad tran-
scription factor, depending on the cellular context and
nuclear components that recruit Smad to speciﬁc target
genes.
9 TGF-b signals to the nucleus by binding to a speciﬁc
pair of membrane receptors, type I (TbR-I) and type II
(TbR-II), that contain a cytoplasmic serine–threonine
kinase domain.
10 Binding of the ligand to TbR-II results in
the formation of a TbR-I/TbR-II heteromeric complex and
activation of TbR-II kinase.
10 Activation of TbR-I requires
phosphorylation of the glycine–serine (GS) region by
TbR-II. Activated TbR-I speciﬁcally recognizes and phosphor-
ylates Smad 2 and 3 or R-Smads.
10 This process results in the
release of Smad 2 and unmasking of its nuclear import func-
tion, thereby leading to rapid accumulation of the activated
Smad complex in the nucleus.
10–12 Smad 4 functions as a
shared partner or Co-Smad and is required for transcrip-
tional complexes to assemble. Once in the nucleus, acti-
vated Smad associates with partner DNA-binding co-factors
that contact Smad and a speciﬁc DNA sequence, thereby
resulting in transcription activation or repression.
9,11
TGF-b receptor signalling is negatively regulated by
FK506-binding protein (FKBP) 12, an abundant and highly con-
served 12 kDa cytosolic protein that exerts peptidyl–prolyl
isomerase activity.
13 FKBP12 regulates fundamental aspects
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 ofcellbiology,duetospeciﬁcprotein–proteininteractionsand
modulation of partner conformation and activity.
14 Among its
multiple biological functions, FKBP12 is a common inhibitor
of TGF-b type I receptors.
13,15 Indeed, it binds to the GS
region, thereby blocking access to activators. In line with this
concept, the TGF-b pathway is overactive in ﬁbroblasts from
FKBP12-knock out mice.
16 FK506, the canonical ligand of
FKBP12, promoted TGF-b receptor transphosphorylation in a
mink epithelial cell line.
15 FK506 is a macrolide compound iso-
latedfromStreptomycestsukubaensis
17andhaspotentimmu-
nosuppressive properties.
18,19 Structurally, FK506 has two
domains, a domain bound by FKBP12 and an effector domain
that, together with FKBP12, forms a composite surface that
interacts with calcineurin, thereby inhibiting its phosphatase
activity.
20 Calcineurin is activated by Ca
2þ-dependent signal
transduction events, such as T-lymphocyte activation, and in
turn dephosphorylates the cytoplasmic subunit of the nuclear
factor of activated T (NFAT) cells, thereby allowing its translo-
cationtothenucleuswhereitassociateswithanuclearsubunit
to form the fully active NFAT complex.
21 NFAT is an essential
component of the transcriptional apparatus required for the
expression of IL-2 and other cytokine genes, including
interleukin-3, interferon g, and tumour necrosis factor a.
22
As an immunosuppressive agent, FK506 is approximately 100
times more potent than cyclosporine.
23 Cytokines released in
the site of arterial injury, as occurs, for example, after
balloon angioplasty, play an important role in inﬂammation
and restenosis.
24 Because some anti-restenosis devices used
in interventional cardiology release FK506,
25 the aim of our
study was to investigate whether such compound can activate
the TGF-b signal in VSMCs and affect cell proliferation. This in
vitro study can provide possible mechanisms governing vascu-
lar remodelling, after FK506-eluting stent implantation.
2. Methods
2.1 Cell culture and reagents
VSMCs were human aortic smooth muscle cells purchased from
Cambrex Bio Science (Cambrex Profarmaco, Milan, Italy). The
cells were cultured in Clonetics SmGM-3 BulletKit medium, accord-
ing to the manufacturer’s instructions. They were starved of sup-
plement growth factors for 48 h, after which FK506 or TGF-b was
added to the medium. The experiments were performed when
cells were at the 6–10 passage. FK506, TGF-b, and cyclosporin
(Sigma Aldrich, St Louis, MO, USA) were used at the doses indicated
under the Results section. SB 431542,
8 which inhibits receptors of
the TGF-b superfamily type I activin receptor-like kinase (ALK),
was purchased from Sigma Aldrich and used at the concentration
of 5 mM.
2.2 Cell lysates and Western blot assay
Whole-cell lysates were prepared by homogenization in the modi-
ﬁed RIPA buffer. The lysate was cleared by centrifugation at
14 000 rpm for 20 min. The lysate was run on SDS–polyacrylamide
gel electrophoresis, transferred onto a membrane ﬁlter (Cellulose-
nitrate, Schleider and Schuell, Keene, NH, USA), and incubated
with the primary antibody.
The antibody against phospho (p) Smad2 (Ser 465/467) (rabbit
polyclonal; Chemicon, Temecula, CA, USA), Smad4, and pErk
(mouse monoclonal; Santa Cruz Biotechnology, Santa Cruz, CA,
USA), cyclin D1 and Smad 2/3 (rabbit polyclonal; Santa Cruz
Biotechnology), pAkt, pmTOR, and extracellular signal-regulated
kinase (Erk) 1/2 (rabbit polyclonal, Cell Signaling Technology,
Danvers, MA, USA), FKBP12 (rabbit polycolonal; Santa Cruz Biotech-
nology) collagen type I (mouse monoclonal, clone SP1D8, Develop-
mental Studies Hybridoma Bank, Iowa City, IA, USA) were all used
diluted 1:200. After a second incubation with peroxidase-
conjugated anti-rabbit IgG or anti-mouse IgG (Santa Cruz Biotech-
nology), the blots were developed with the ECL system (Supersignal
West Pico, Celbio, Pierce, Rockford, IL, USA).
2.3 Immunoﬂuorescence and microscopy
To investigate VSMC growth on bare stents, cells were plated onto
35 mm plastic dishes together with a stent in the absence or pre-
sence of 100 ng/mL FK506. After 9 days of culture, the stents
were removed from the dishes, ﬁxed in 4% paraformaldehyde
in PBS for 20 min and cells were permeabilized for 5 min in 0.1%
Triton X-100 in PBS. Cells were then washed twice in PBS
and nuclei were stained with 20-(4-hydroxyphenyl)5-(4-methyl-
1-piperazynyl)–2,50-bi(1H-benzimidazoil)-6-(1-methyl-4piperazyl)
benzimidazole trihydrochloride (Hoechst) 33258 ﬂuorescent reagent
(0.5 mg/mL in PBS) (Sigma Aldrich) for 10 min. Stents were
mounted on glass slides with PBS containing 50% glycerol. Stained
ﬂuorescent nuclei were visualized on a Zeiss Axioscop 2 microscope
(Zeiss, Gottingen, Germany) and images were taken with a Zeiss
Axiocam.
To investigate Smad nuclear translocation, VSMCs were plated
onto 12 mm glass coverslips. Cells were treated with 10 ng/mL
TGF-b or with 100 ng/mL FK506 for 60 min. Cells used as control
were treated with the medium alone. Cells were ﬁxed in 4% paraf-
ormaldehyde in PBS for 20 min, washed twice for 5 min each time,
with 50 mM NH4Cl in PBS permeabilized for 5 min in 0.1% Triton
X-100 in PBS. Cells were then blocked in 1% BSA in PBS for 1 h
and washed twice in PBS. A mouse monoclonal anti-Smad4
diluted 1:100 in PBS 0.5% BSA for 1 h in a humidiﬁed atmosphere
served as primary antibody. Cells were then extensively washed
in PBS before staining with secondary goat anti-mouse Alexa
Fluor 488 conjugated (Molecular Probe, Invitrogen Corporation,
Carlsbad, CA, USA). Nuclei were counterstained with Hoechst
33258 (0.5 mg/mL in PBS) (Sigma Aldrich) for 10 min. Finally,
cells were washed in PBS and mounted on glass slides with PBS con-
taining 50% glycerol.
Immunoﬂuorescence analysis was performed using a confocal
laser scanner microscope (LSM 510 Meta; Zeiss). The lambda of
the argon ion laser was set at 488 nm. Fluorescence emission was
revealed by BP 505–530 band pass ﬁlter for Alexa Fluor 488.
Nuclear Hoechst 33258-stained cells were excited with mercury
lamps and images acquired in a single channel using a 460–489
band pass ﬁlter. Double-staining immunoﬂuorescence images were
acquired in the green and blue channels at a resolution of 1024  
1024 pixels.
2.4 Proliferative assays
To measure the concentration of DNA in VSMCs that were grown on
stents, cells were seeded onto six-well plates with a stent in each
well, in the absence or presence of 100 ng/mL FK506. The stents
were removed from wells after 9 days of culture and introduced
in a tube with 1 mL of a permeabilizing solution containing
Hoechst 33258 (0.5 mg/mL in 0.1% sodium citrate, w/v; 0.1%
Triton X-100, v/v). After 30 min incubation at room temperature,
tubes were vortexed and centrifuged at 400g for 10 min to collect
cells. The supernatant was discarded, stents were examined using
a microscope to verify the absence of cells, and the pellets were
resuspended in 500 mL of RIPA buffer. The DNA in lysates was read
with a ﬂuorimeter at an excitation wavelength of 354 nm and at
an emission of 461 nm.
Cell proliferation was measured with 5-bromo-20-deoxy-uridine
labelling and with a detection kit (Detection Kit II, Roche Diagnostics
Corporation, Indianapolis, IN, USA) following the manufacturer’s
instructions. Brieﬂy, cells were plated onto 24-well plates in the
A. Giordano et al. 520
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 absence or presence of different doses of FK506 or 10 ng/mLTGF-b.
After incubation for 3 days, 10 mM BrdU was added to the cultures,
and, after a further 4 h, cells were collected, ﬁxed with ethanol,
and incubated with anti-BrdU monoclonal antibody. The per cent
of BrdU incorporation was measured in ﬂow cytometry (FACScan
Becton Dickinson, San Diego, CA, USA).
2.5 Immunoprecipitation of membranes
Cells harvested after a 2 h incubation with FK506 were osmotically
lysed in distilled water and subjected to three cycles of rapid freez-
ing and thawing, after addition of protease inhibitors and phospha-
tase inhibitors. During thawing, the extract was sonicated for
10 min. After obtaining a homogeneous suspension, protein concen-
tration was determined with the Bradford method and 500 mgo f
protein extract was pre-cleared for 1 h. For immunoprecipitation,
15 mg anti-TbR-I (rabbit polyclonal H-100) or anti-FKBP12 (goat
polyclonal N-19; Santa Cruz Biotechnology) was added together
with 25 mL protein A-Sepharose (Santa Cruz Biotechnology), and
precipitation took place overnight with rotation at 48C. Samples
were separated by 14% SDS–PAGE together with a molecular
weight marker and transferred onto membrane ﬁlter.
2.6 Cell transfection and short interfering RNA
Twenty-four hours before transfection of two different short inter-
fering (si)RNAs corresponding to the target sequences GCTTGAA-
GATGGAAAGAAA and GAAACAAGCCCTTTAAGTT of the FKBP12 gene
(Qiagen, Valencia, CA, USA) or of a scrambled duplex as control,
VSMCs were incubated in medium without antibiotics at the concen-
tration of 2.5   10
5/mL to obtain 30–50% conﬂuence at the time of
transfection. The siRNA or the scrambled oligo was transfected at
the ﬁnal concentration of 50 nM using Metafectene (Biontex,
Munich, Germany) according to the manufacturer’s recommen-
dations, and 72 h later, cells were harvested to prepare cell
lysates. The effect of siRNA on protein expression was determined
by Western blot.
2.7 Statistical analysis
The results reported are the mean and the standard deviation of
independent experiments. The statistical signiﬁcance of differences
between means was estimated using Student’s t-test. Values of P  
0.05 were considered statistically signiﬁcant.
3. Results
3.1 Transforming growth factor-b stimulates
DNA and collagen synthesis in vascular
smooth muscle cells
TGF-b stimulates proliferation of VSMCs and matrix protein
production.
2–6 We conﬁrmed this observation in our experi-
mental model of human VSMCs. Indeed, TGF-b (10 ng/mL)
signiﬁcantly increased VSMC proliferation as measured by
BrdU incorporation (Figure 1A). In ﬁve experiments, each
carried out in triplicate, the proportion of cells incorporat-
ing BrdU in their DNA was signiﬁcantly higher (P ¼ 0.02)
in TGF-b-stimulated cells than in unstimulated cells
(Figure 1A). In accordance with the results of BrdU assay,
Western blot showed enhanced levels of cyclin D1 in TGF-
b-cultured cells (Figure1B). Furthermore, collagen type I
levels were increased in whole-cell lysates prepared from
VSMCs cultured with TGF-b (Figure 1C). Taken together,
these ﬁndings support the concept that TGF-b is a promoter
of cell proliferation and extracellular matrix formation
in VSMCs.
3.2 FK506 activates the transforming growth
factor-b signalling
FK506 activates receptor I transphosphorylation, which is
important for kinase activity and signal transduction.
15 We
investigated whether FK506 activates the TGF-b signal in
VSMCs. Using Western blot assay, we studied the kinetics
of pSmad2 levels in whole-cell lysates prepared from
VSMCs cultured with 10 ng/mL TGF-b or 100 ng/mL FK506.
We found that the levels of pSmad2 in VSMCs cultured
with TGF-b increased as early as 2 min after incubation
and persisted for 3–4 h, after which they decreased
(Figure 2A). Similar results were obtained with cells
Figure 1 Transforming growth factor-b stimulates vascular smooth muscle cell proliferation and collagen production. (A) Flow cytometric histograms of BrdU
incorporation in vascular smooth muscle cells. Cells were cultured with and without 10 ng/mL transforming growth factor-b. After incubation for 3 days, 10 mM
BrdU was added to the cultures and 4 h later cells were collected, ﬁxed with ethanol, and incubated with anti-BrdU-FITC monoclonal antibody. The bar indicates
the per cent of cells incorporating BrdU in their DNA. The data presented are representative of ﬁve different experiments, each performed in triplicate.
(B) Western blot assay of cyclin D1 levels in whole-cell lysates (30 mg) of vascular smooth muscle cells incubated with 10 ng/mL transforming growth factor-b
for 0, 30 min, 3, 4, and 16 h. Similar results were obtained in other two different experiments. (C) Western blot assay of collagen type I levels in whole-cell
lysates (30 mg) of vascular smooth muscle cells treated with 10 ng/mL transforming growth factor-b for 0, 8, and 16 h. The data of collagen upregulation was
conﬁrmed in another two independent experiments.
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 cultured with FK506 (Figure 2B). We investigated whether
the effect of FK506 was dose-dependent. As shown in
Figure 2C, the optimal dose of FK506 for Smad2 activation
was  50 ng/mL. Smad phosphorylation was not found in
VSMCs cultured with another calcineurin inhibitor, cyclos-
porine, which binds to cyclophilin A.
14 This ﬁnding conﬁrms
the speciﬁcity of the effect observed with FK506. Receptor-
mediated phosphorylation increases the afﬁnity of Smad2
for Smad4 and rapid accumulation of the complex in the
nucleus.
11,12 Immunoﬂuorescence of VSMCs stained with
anti-Smad4 and confocal microscopy showed that FK506
induced nuclear translocation of Smad (Figure 3). Taken
together, these results suggest that FK506 activates TGF-b
signalling in VSMCs.
3.3 FK506 removes FKBP12 from TbR-1 thereby
activating the signal
Displacement of FKBP12 from its binding to the GS region
of TbR-1 is essential for the activation of the kinase
activity.
13 To investigate whether FK506 displaces
FKBP12 binding, we incubated the cells with or without
100 ng/mL FK506 and prepared whole-cell lysates for
co-immunoprecipitation experiments. As shown in Figure 4A,
TbR-1 co-immunoprecipitated with FKBP12 in unstimulated
VSMCs but not in FK506-stimulated VSMCs, suggesting that
the drug removed FKBP12. To determine whether this
effect was sufﬁcient to activate the kinase activity, we
depleted the cells of FKBP12 using two different siRNAs
and measured the levels of phosphorylated Smad2. We
found that pSmad levels were remarkably increased in
FKPB12-depleted cells (Figure 4B). Taken together these
ﬁndings suggest that FKBP12 controls activation of the
TGF-b signal in VSMCs.
3.4 FK506 promotes vascular smooth muscle cell
growth
We next studied the effect of FK506 on VSMC growth. Cells
were incubated with FK506 and proliferation was investi-
gated by measuring BrdU incorporation in cell DNA. As
shown in Figure 5A, the proportion of cells incorporating
BrdU dose-dependently increased in FK506 cultures. The
levels of b-catenin, Erk, protein kinase B (PkB/Akt), and
the mammalian target of rapamycin (mTOR) were increased
(Figure 5B), which indicates that FK506 activated the
Figure 2 FK506 activates the transforming growth factor-b receptor I kinase
activity in vascular smooth muscle cells. (A) Kinetics of transforming growth
factor-b-induced Smad 2 phosphorylation. Western blot assay of pSmad 2 (Ser
465–467) levels in whole-cell lysates (30 mg) of vascular smooth muscle cells
incubated with 10 ng/mL transforming growth factor-b for 0, 2, 5, 15, 30, 60,
120, 180, and 240 min. (B) Kinetics of FK506-induced Smad 2 phosphorylation.
Western blot assay of pSmad 2 (Ser 465–467) levels in whole-cell lysates
(30 mg) of vascular smooth muscle cells incubated with 100 ng/mL FK506
for 0, 2, 5, 15, 30, 60, 120, 180, and 240 min. (C) Dose/response effect of
FK506 on Smad 2 phosphorylation. Western blot assay of pSmad 2 (Ser 465–
467) levels in whole-cell lysates (30 mg) of vascular smooth muscle cells incu-
bated with 1, 20, 50, 100, and 250 ng/mL FK506 and 300 ng/mL cyclosporin,
as control, for 1 h. Smad 2/3 was used as loading control. Each experiment
presented was performed at least three times.
Figure 3 FK506 induces Smad nuclear translocation. Cells were incubated
with control medium (A and B) or treated with 10 ng/mL transforming
growth factor-b (C and D) or 100 ng/mL FK506 (E and F). After incubation
for 1 h, cells were stained with Smad 4 (A, C and E) to visualize protein local-
ization, or Hoechst 33258 (B, D, and F) to visualize nuclei. Localization of
Smad4 was both cytosolic and nuclear in control cells (A), whereas it was
clearly nuclear in cells treated with transforming growth factor-b (C)o r
FK506 (E). Bar 10 mm. The data were conﬁrmed at least in ﬁve different
experiments.
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 signalling pathways governing cell proliferation. Consistent
with this ﬁnding, the cell cycle regulator cyclin D1 was
induced in FK506-treated cells. Similar to TGF-b, FK506
increased collagen type I synthesis (Figure 5C). FK506 strik-
ingly stimulated VSMC proliferation even in condition which
does not favour cell adhesion, as it occurs in the case of
metal surface.
26 Figure 5D shows results of a 9 day culture
of cells seeded onto plates containing a metal stent and incu-
bated with or without 100 ng/mL FK506. The metal stent was
not invaded by proliferating cells in culture dishes without
FK506. In fact, very few nuclei were visualized on stents
removed by such dishes. Normally, once the cells reach the
conﬂuence, they detach from the plate and die. But, in the
presence of FK506, cell growth continued on the metal
support, suggesting that cells were refractory to death.
Although the ﬁnding of growth on bare stents has no transla-
tional implication, it strengthens the hypothesis that FK506
exerts a pro-survival and proliferative effect. Stents were
stained with Hoechst 33258 and examined by microscopy
and ﬂuorimetrically to evaluate DNA concentrations in the
nuclei. Results of absorbance from three different experi-
ments were 32.121+2.001 and 77.126+1.691 OD for cells
cultured with and without FK506, respectively.
3.5 Selective inhibition of transforming
growth factor-b type I receptor kinase
prevents FK506-induced proliferation of vascular
smooth muscle cells
To verify that the proliferative response to FK506 depended
on activation of the TGF-b signal, we used SB431542, which
is a selective inhibitor of TGF-b type I ALK receptors. This
compound efﬁciently inhibited receptor kinase activity, as
indicated by the reduced levels of pSmad in VSMCs cultured
with FK506 plus SB431542 compared with the levels of cells
cultured with FK506 alone (Figure 6A). Treatment of the
cells with SB431542 dramatically inhibited proliferation in
FK506 cultures (Figure 6B), which suggests that Smad 2
phosphorylation is essential for transduction of the prolif-
erative signal stimulated by FK506.
4. Discussion
Here we demonstrate that the immunosuppressant FK506 or
‘tacrolimus’ acts as a growth factor for VSMCs. This com-
pound is structurally related to rapamycin, which signiﬁ-
cantly prevents the incidence of in-stent restenosis
27 when
administered coated to eluting stents in angioplastic pro-
cedures. FKBP12 is the intracellular ligand of both FK506
and rapamycin.
18–20 Although both drugs bind to the same
immunophilin receptor, the resulting immunophilin–drug
complexes interfere with distinct intracellular signalling
pathways. The interaction between FKBP12 and FK506
results in a complex that inhibits calcineurin phosphatase,
18
which controls lymphocyte activation,
19 whereas the
binding of FKBP12 to rapamycin produces a complex that
inhibits mTOR
28 downstream from the phosphatidyl-inositol
3 kinase (PI3k)/Akt-PkB survival pathway.
29 There is great
interest in therapeutically targeting VSMC growth with
agents delivered by stents implanted in coronary vessels.
27
As a step in this direction, polymer-free stents coated with
FK506 have been developed.
25
Figure 4 FK506 activates TbR-I by removing FKBP12. (A) FKBP12/TbR-I interaction in vascular smooth muscle cells. Total lysates, prepared from cells incubated
with and without FK506 (100 ng/mL) for 2 h, were subjected to immunoprecipitation (IP) with anti-TbR-I or FKBP12 antibody. Immunoprecipitated and total
lysates were then subjected to Western blot with anti-TbR-I or -FKBP12. The data were conﬁrmed in another independent experiment. (B) Western blot
assay of FKBP12 and pSmad 2 levels in total lysates prepared from non-transfected vascular smooth muscle cells, from vascular smooth muscle cells transfected
with a scrambled duplex or with two different FKBP12 siRNAs, 3 days after transfection. Smad 2/3 and actin were used as loading control. The data were repre-
sentative of three different experiments.
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 It is noteworthy that migration and proliferation of smooth
muscle cells in injured vessels are stimulated by cytokines
released by inﬁltrating mononuclear cells.
24 Therefore,
FK506, which is a potent inhibitor of lymphocyte acti-
vation,
19,20,30 appeared to be a good candidate to counteract
this phenomenon. Nevertheless, contrary to rapamycin,
which exerts immunosuppressant,
20,30 anti-proliferative,
29
and pro-apoptotic
31 effects, little is known about the effect
of FK506 on cell growth. Here we show that FK506 activates
the TGF-b signal in VSMCs. In fact, FK506 increased levels
of phosphorylated Smad and nuclear translocation of the
Smad complex in VSMCs.
This ﬁnding is in accordance with studies showing that
FKBP12 ligands, i.e. FK506 and rapamycin, promote TGF-b
receptor transphosphorylation.
15 We found that FK506 pro-
voked FKBP12 release from the cytoplasmic tail of the
TGF-b receptor. This displacement was apparently sufﬁcient
to trigger the receptor kinase activity, as suggested by the
appearance of phosphorylated Smad in cells depleted of
FKBP12.
TGF-b plays an important role in promoting excess intimal
hyperplasia after vascular injury, thereby concurring in rest-
enosis after coronary angioplasty.
1–6 Consistent with this
notion, TGF-b enhanced proliferation and extracellular
matrix production in our speciﬁc cellular context of human
VSMCs, as indicated by increased BrdU incorporation,
cyclin D1 upregulation, and induction of collagen type 1
synthesis.
We found that, similar to TGF-b, FK506 stimulated cell
growth. We thus investigated the pathways governing vascu-
lar remodelling and VSMC proliferation in cells cultured with
FK506. Our data show that FK506 increased the levels of
b-catenin, a key regulatory molecule of the highly con-
served Wnt pathway
32 that controls the dynamic process of
vascular remodelling.
33 Several lines of evidence implicate
b-catenin in the development of intimal thickening.
33–35
Figure 5 FK506 stimulates vascular smooth muscle cell proliferation. (A) Dose/response effect of FK506 on vascular smooth muscle cell proliferation. Graphic
representation of mean values and standard deviations of per cent of cells incorporating BrdU in their DNA, in ﬁve different experiments, each performed in
triplicate. Cells were cultured with and without 20, 100, and 250 ng/mL FK506. After incubation for 3 days, 10 mM BrdU was added to the cultures and 4 h
later cells were collected, ﬁxed with ethanol, and incubated with anti-BrdU monoclonal antibody. The per cent of BrdU incorporation, measured by ﬂow cyto-
metry, was signiﬁcantly increased by FK506 at the doses of 100 ng/mL (P ¼ 0.003) and 250 ng/mL FK506 (P ¼ 0.001), compared with that found in cells cultured
with medium alone. (B) FK506 activates signalling kinases involved in cell proliferation. Western blot assay of b-catenin, pErk, pAkt, pmTOR, and cyclin D1 levels
in vascular smooth muscle cell lysates prepared from cells cultured with 100 ng/mL FK506, for 0, 30 min, 4, 8, 12, 16, and 24 h. Erk 1/2 and Akt were used for
loading control. Comparable results were obtained in two other different experiments. (C) Western blot assay of collagen type I levels in whole-cell lysates of
vascular smooth muscle cells treated with 100 ng/mL FK506 for 16 h. The result conﬁrmed two other independent experiments. (D) FK506 stimulates vascular
smooth muscle cell growth on a metal stent. Vascular smooth muscle cells were cultured in dishes containing a metal stent with and without 100 ng/mL FK506.
After 9 days of culture, the stent was removed from the dish and nuclei were stained with Hoechst 33258 and visualized with a Zeiss Axioscop 2. Bar 25 mm. In
three different experiments, the mean absorbance was 32.121+2.001 and 77.126+1.691 OD for cells cultured with and without FK506, respectively.
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 In an in vivo model of intimal thickening, b-catenin
expression co-localized in proliferating VSMC within the
developing intima.
34 b-catenin regulates VSMC proliferation
in response to stimulation by growth factors via the regu-
lation of the cell cycle genes cyclin D1 and p21.
34 Interest-
ingly, the Wnt/b-catenin pathway can be activated in
response to various stimuli,
36 including TGF-b.
32,37,38 In
agreement with this concept, we found that FK506-induced
proliferation was prevented when the TGF-b type I receptor
kinase was inhibited. The increase in b-catenin levels was
accompanied by the activation of Erk and Akt, which are
important mediators of b-catenin signalling.
39,40 Further-
more, consistent with reports that mTOR can be activated
through tuberin phosphorylation by both Erk
41 and Akt,
42
mTOR levels were also increased in FK506-treated VSMCs.
It is noteworthy that all these signalling kinases drive bio-
chemical networks that directly regulate the expression of
genes responsible for cell cycle progression.
41 In accordance
with this ﬁnding, we found that the expression of cyclin D1
was enhanced in FK506 cultures. The Akt pathway also
exerts a primary role, synergistically driven by mTOR, in
cell survival.
41,43 Indeed, stimulation of Akt produces phos-
phorylation of downstream targets involved in apoptosis
control.
43 Phosphorylation of FOXO3A, a member of the
forkhead family of transcription factors, leads to inhibition
of its transcription activity. This results in the down-
regulation of the pro-apoptotic BH3-only molecule, Bim.
43
Moreover, Akt-induced phosphorylation of another pro-
apoptotic Bcl-2 family member protein, namely Bad,
causes its dissociation from the complex with Bcl-xL,
thereby allowing cell survival.
43 Therefore, Akt activation
may result in resistance to death-inducing signals possibly
released in the site of vascular injury.
Although rapamycin also activates TGF-b receptor signal-
ling because of the binding to FKBP12 (not shown), it did not
increase the levels of cyclin D1 and collagen type 1 (not
shown). This ﬁnding suggests that the proliferative and pro-
ﬁbrotic stimuli are inhibited downstream the pathway
consequent to mTOR blockage by FKBP12/rapamycin
complex itself. Also in the case of immunosuppression, rapa-
mycin acts on the signalling pathway of T-cell activation
downstream to FK506. In fact, while FK506 blocks transcrip-
tion of the IL-2 gene, rapamycin has no effect on gene tran-
scription but rather has a potent inhibitory effect on growth
factor-induced proliferation.
Our ﬁndings support the conclusion that FK506 is a poten-
tial stimulus of neointima formation when administered
coated to intravascular stents. This implies that, although
FK506 dampens cytokine-induced VSMC migration and pro-
liferation through its immunosuppressant mechanism, it
exerts a direct proliferative effect on these cells. There-
fore, the clinical outcome of patients receiving FK506-
eluting stents depends on the balance between these
opposite effects. Curiously, the stent name, ‘Janus’, who
is the Roman god with two faces looking in opposite direc-
tions, reﬂects our conclusions.
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